Corticosterone Clinical Trials

Size	Price	Qty
50mg	USD 147
200mg	USD 297

Clinical Trials

Several clinical trials evaluate or monitor corticosterone across diverse indications, including prostate cancer, acne vulgaris, autistic disorder, coxarthrosis, and physiological assessments of newborn genitalia. Sponsored by academic centers and industrial partners, these studies encompass observational protocols alongside interventional trials ranging from Phase 1 to Phase 3. Across this landscape, recruitment statuses vary from completed and actively recruiting to unknown.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05903716	Recruiting	Acne Vulgaris	Marmara University	2022-09-15	--
NCT04930471	Unknown status	Autistic Disorder	Insel Gruppe AG University Hospital Bern\|Lindenhofstiftung	2021-06	--
NCT02826278	Unknown status	Newborn Genitalia	Hospices Civils de Lyon	2014-10	--
NCT01666314	Completed	Prostate Cancer	Millennium Pharmaceuticals Inc.\|Takeda	2012-08-20	Phase 1\|Phase 2
NCT01079455	UNKNOWN	Coxarthrosis	University Hospital Pellenberg	2010-05	PHASE3
NCT01186484	Completed	Prostatic Neoplasms	Janssen Pharmaceutical K.K.	2010-06-01	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Corticosterone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an endogenous adrenocortical steroid, corticosterone binds intracellular glucocorticoid and mineralocorticoid receptors, triggering nuclear translocation that inhibits downstream pro-inflammatory gene transcription and alters cellular metabolic signaling. This receptor-mediated modulation suppresses cellular proliferation and immune activation, providing clinical relevance for evaluating corticosteroid dynamics in conditions such as prostate cancer, acne vulgaris, and coxarthrosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).